Market Intelligence, Clinical Progress, and High-Purity Reagents for Sarcoma and Regenerative Medicine Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CDH15 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CDH15 ECD-Fc Fusion Protein High purity (>95%), Endotoxin Controlled (<1.0 EU/μg). Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View CDH15 Products |
| Gene Delivery | CDH15 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and functional conformation assays. |
View CDH15 Products |
| Benchmark Ab | Anti-CDH15 Benchmark Antibody Recombinant positive control for assay validation and binding competition. |
View CDH15 Products |
| Validator | CDH15 siRNA Set Target-specific knockdown verification to eliminate false-positive binding signals. |
View CDH15 Products |
| Related Target A | CDH2 (N-cadherin) Essential for counter-screening to prevent cardiac and neural off-target toxicity. |
View CDH2 Products |
| Related Target B | CDH1 (E-cadherin) Critical homolog for selectivity profiling to ensure lineage-specific targeting. |
View CDH1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Calcium-dependent conformation preservation | Purified in calcium-optimized buffer systems to maintain native cadherin fold |
| Subfamily counter-screening (CDH1, CDH2) | Highly purified homolog panel proteins strictly verified by mass spectrometry |
| Lack of controls | Recombinant sequence-verified benchmark antibodies included for assay alignment |
| False positives in cell-based screening | Sequence-validated siRNA sets included for target-specific knockdown verification |
Live CDH15 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CDH15 therapeutics is intensifying, with major players shifting focus from traditional mAbs to antibody-drug conjugates (ADCs) and targeted cell therapies for sarcomas. As first-generation therapies reach the clinic, the next wave of R&D is targeting highly specific epitopes that differentiate CDH15 from other classical cadherins, minimizing systemic toxicity while maximizing therapeutic index in rhabdomyosarcoma and muscle-wasting indications.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC (Antibody-Drug Conjugate) | Biotech Startups, Academic Consortia | Rhabdomyosarcoma, Synovial Sarcoma | Internalization Assay (Need high-purity ECD-Fc with native glycosylation) |
| Monoclonal Antibody (Blocking) | Regenerative Medicine Institutes | Cachexia, Muscular Dystrophy | Cell-cell Adhesion Assay (Need Lentivirus for stable cell line construction) |
| CAR-T / Cell Therapy | Oncology Research Centers | Solid Tumors (CDH15+ Myogenic Lineage) | Selectivity Assay (Need CDH1 & CDH2 proteins for cross-reactivity profiling) |